GlassScriptPhysician profile
Robert M Carlile
NPI 1740575307
$427,524.90
in general payments reported to CMS, 2019-2025
92 companies · $103K in 2025
The $103K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $45K · 2021: $58K · 2022: $70K · 2023: $36K · 2024: $75K · 2025: $103K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $151K · Travel and Lodging: $22K · Food and Beverage: $21K · Consulting Fee: $20K · Education: $73.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $151,489.50 |
| Travel and Lodging | $21,837.69 |
| Food and Beverage | $20,512.13 |
| Consulting Fee | $20,427.50 |
| Education | $73.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $161,623.96 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Abbvie INC. | $122,529.12 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Lilly USA, LLC | $72,491.21 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Allergan, INC. | $18,655.49 | 2019-2021 | |
| C2n Diagnostics, LLC | $13,680.84 | 2025 | Precivityad2 |
| Ucb, INC. | $4,901.10 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Novartis Pharmaceuticals Corporation | $3,871.24 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $3,293.00 | 2019-2025 | Nuplazid |
| Amgen INC. | $3,122.35 | 2019-2025 | Uplizna, Aimovig |
| Genzyme Corporation | $2,717.34 | 2019-2025 | |
| Argenx US, INC. | $1,768.81 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Emd Serono, INC. | $1,439.24 | 2019-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $1,287.39 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Neurocrine Biosciences, INC. | $1,096.40 | 2022-2025 | Ingrezza, Ongentys |
| Mdd US Operations, LLC | $870.38 | 2019-2025 | Gocovri, Xadago, Myobloc |
Show all 87 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $794.48 | 2023-2025 | |
| Pfizer INC. | $751.07 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $664.05 | 2019-2025 | Rytary, Lyvispah, Crexont |
| Sk Life Science, INC. | $627.67 | 2020-2024 | |
| Lundbeck LLC | $618.17 | 2020-2025 | Vyepti, Rexulti |
| Sumitomo Pharma America, INC. | $560.96 | 2023-2025 | Orgovyx, Aptiom, Gemtesa |
| Csl Behring | $522.17 | 2019-2025 | Hizentra |
| Janssen Pharmaceuticals, INC | $453.09 | 2021-2022 | |
| Kyowa Kirin, INC. | $445.51 | 2019-2024 | Nourianz |
| Celgene Corporation | $439.73 | 2022-2025 | Zeposia |
| Alexion Pharmaceuticals, INC. | $422.96 | 2019-2025 | Ultomiris, Soliris |
| Sunovion Pharmaceuticals INC. | $416.27 | 2019-2022 | |
| Banner Life Sciences, LLC | $393.77 | 2021-2024 | |
| Eisai INC. | $379.38 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $359.05 | 2020-2021 | |
| Genentech USA, INC. | $339.56 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Otsuka America Pharmaceutical, INC. | $324.85 | 2023-2025 | Rexulti, Nuedexta |
| Acorda Therapeutics, INC | $284.54 | 2019-2023 | Inbrija |
| Supernus Pharmaceuticals, INC. | $277.20 | 2019-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $261.09 | 2023-2025 | Hyqvia |
| Alnylam Pharmaceuticals INC. | $250.82 | 2021-2025 | Onpattro |
| Axsome Therapeutics, INC. | $238.03 | 2023-2025 | Symbravo, Auvelity, Sunosi |
| Biohaven Pharmaceutical Holding Company LTD. | $237.54 | 2022 | |
| Vanda Pharmaceuticals INC. | $217.44 | 2021-2025 | Ponvory, Hetlioz |
| Avanir Pharmaceuticals, INC. | $212.21 | 2020-2022 | |
| Upsher-Smith Laboratories LLC | $201.80 | 2019-2022 | |
| Assertio Therapeutics, INC. | $191.30 | 2019-2020 | |
| Bausch Health US, LLC | $190.38 | 2019-2020 | |
| Merz Pharmaceuticals, LLC | $187.55 | 2022-2025 | Xeomin, Inbrija, Ampyra |
| Akcea Therapeutics, INC. | $164.77 | 2019-2021 | |
| Adamas Pharmaceuticals, INC. | $159.19 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $155.87 | 2021-2025 | Wainua |
| Amylyx Pharmaceuticals, INC. | $148.67 | 2023-2024 | Relyvrio |
| Catalyst Pharmaceuticals, INC. | $147.24 | 2020-2025 | Fycompa |
| Tanabe Pharma America, INC. | $144.67 | 2019-2025 | Radicava |
| Impel Pharmaceuticals INC. | $139.56 | 2022-2023 | Trudhesa |
| Grifols USA, LLC | $130.34 | 2019-2025 | Gamunex-C |
| Boston Scientific Corporation | $115.63 | 2019-2024 | Wavewriter Alpha Prime 16, Watchman Flx, Spectra Wavewriter |
| Ge Healthcare | $109.99 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $97.69 | 2019 | |
| Mallinckrodt Hospital Products INC. | $92.95 | 2020-2025 | Acthar |
| Medtronic, INC. | $92.74 | 2022-2025 | Intellis Adaptivestim |
| E.R. Squibb & Sons, L.L.C. | $92.34 | 2020-2025 | Cobenfy, Zeposia |
| Horizon Therapeutics Plc | $84.28 | 2021-2023 | Uplizna |
| F. Hoffmann-La Roche Ag | $80.00 | 2025 | |
| Averitas Pharma INC. | $72.39 | 2025 | Qutenza |
| Jazz Pharmaceuticals INC. | $72.02 | 2022-2025 | |
| Currax Pharmaceuticals LLC | $71.66 | 2020-2023 | Onzetra Xsail |
| Scilex Pharmaceuticals INC. | $67.94 | 2023-2024 | Ztlido |
| Ultragenyx Pharmaceutical INC. | $65.98 | 2023-2025 | Dojolvi |
| Avion Pharmaceuticals | $51.37 | 2022-2023 | Dhivy |
| Almatica Pharma LLC | $49.01 | 2021 | |
| Livanova USA, INC. | $48.84 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $46.77 | 2023-2024 | Quviviq |
| Abbott Laboratories | $42.48 | 2022-2023 | Infinity |
| Xeris Pharmaceuticals, INC. | $40.42 | 2024-2025 | Keveyis |
| Bayer Healthcare Pharmaceuticals INC. | $34.22 | 2019 | |
| Ani Pharmaceuticals, INC. | $28.47 | 2025 | Purified Cortrophin Gel |
| Hospira, INC. | $25.85 | 2022 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $25.00 | 2025 | Kisunla |
| Neurelis, INC. | $24.72 | 2025 | Valtoco |
| Noctrix Health, INC. | $22.96 | 2024 | Nidra |
| Sonex Health, INC. | $21.25 | 2025 | Sx-One Microknife |
| Promius Pharma LLC | $20.92 | 2019 | |
| Aquestive Therapeutics, INC. | $20.63 | 2021 | |
| Insightec,INC | $19.08 | 2025 | Exablate |
| Springworks Therapeutics, INC. | $17.15 | 2025 | Gomekli |
| Greenwich Biosciences, INC. | $17.11 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.34 | 2021 | |
| Medtronic Vascular, INC. | $13.63 | 2020 | |
| Alfasigma USA, INC. | $13.30 | 2021 | |
| Zyla Life Sciences, INC. | $10.95 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$13,057.37 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Carlile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.